Barr Is Latest Generic Firm To Take On FDA’s Patent-Based Exclusivity Policy
This article was originally published in The Tan Sheet
Executive Summary
Barr's lawsuit over 180-day generic marketing rights for Sanofi-Aventis' Allegra-D marks the most recent legal challenge to FDA's patent-based approach to awarding exclusivity